

C-Type Natriuretic Peptide (CNP)(1-22) TFA Biochemical

C-Type Natriuretic Peptide (CNP)(1-22), human TFA

CATALOG #
AAA228025


PRODUCT SYNONYMS

C-Type Natriuretic Peptide (CNP)(1-22) TFA; C-Type Natriuretic Peptide (CNP)(1-22); human TFA; C-Type Natriuretic Peptide (CNP)(1-22) TFA biochemical

PRODUCT SPECIFICATIONS


Purity/Purification	98%
CAS	1966153-17-2
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	C-Type Natriuretic Peptide (CNP)(1-22), human (TFA)(0.01, 0.1, 1, 10, 100, 1000 nM) increases cGMP production in CHO cells expressing human NPR-B in a concentration-dependent manner[1]. PK parameters of CNP immunoreactivity after a single intravenous administration of C-Type Natriuretic Peptide (CNP)(1-22), human (TFA)[1]: Dose (nM/kg) AUC 0-->infinity (pM/min/mL) MRT 0-->infinity (min) T 1/2 (min) CL tot (mL/min/kg) Vd ss (mL/kg) 20 320+/-54 1.02+/-0.18 1.42+/-0.45 63.9+/-11.9 64.2+/-5.1 PK parameters of CNP immunoreactivity after a single subcutaneous administration of C-Type Natriuretic Peptide (CNP)(1-22), human (TFA)[1]: Dose (nM/kg) Cmax (pM/mL) Tmax (min) AUC 0-->infinity (pM/min/mL) MRT 0-->infinity (min) T 1/2 (min) BA (%) 50 9.02+/-3.74 5.0+/-0.0 152+/-73 13.9+/-3.4 10.0+/-5.0 19+/-9 Each value represents the mean+/-SD of 3 rats. MRT=mean residence time, CL tot =total clearance, T 1/2 =half-life period, BA=bioavailability. i.c.v. administration of C-Type Natriuretic Peptide (CNP)(1-22) in a dose of 2 nM induces an increase in the severity of picrotoxin-kindled convulsions 24 and 48 hrs after application of the peptide[3].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure

Pomalidomide-amino-PEG4-NH2, CAS 2331259-44-8



Structure

Pomalidomide-amino-PEG4-NH2, CAS 2331259-44-8

ADDITIONAL INFORMATION

Related Product Information for C-Type Natriuretic Peptide (CNP)(1-22) TFA biochemical	C-Type Natriuretic Peptide (CNP)(1-22), human (TFA), a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP)(1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor.
References	1. Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine. Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11. 2. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://www.aaabiotech.com/biochemical/c-type-natriuretic-peptide-cnp-1-22-tfa/228025>